Binding Site has been chosen as an important diagnostic partner in the Black Swan ‘cure myeloma’ research initiative, sponsored by the International Myeloma Foundation (IMF). The initiative will coordinate an international collaboration led by an elite team of world experts in the field of multiple myeloma. This expert panel has identified the tools needed to confirm the various drug regimens that will achieve a path to a cure, including the use of Binding Site’s Freelite and Hevylite tests.
Freelite is the only test approved by the International Myeloma Working Group for quantifying serum free light chains, and Hevylite is an exciting new development aimed at improving patient monitoring. These blood test technologies are used around the world to assist clinicians in understanding multiple myeloma patients’ course of disease and, importantly, the quality of their response. Together, these tests have been the subject of over 2500 peer-reviewed studies.
“It’s very exciting to see the progress we’re making with the Black Swan research initiative, and it’s quite possible that we will begin to cure a subset of patients in the not too distant future,” said Susie Novis, IMF president and co-founder.
Dr Stephen Harding, Binding Site’s research and development director. Commented: “We have a total commitment to research in this field and Binding Site is delighted to support this IMF initiative aimed at improving patient outcomes.”
www.bindingsite.com
www.myeloma.org